In a report released yesterday, Ryan Zimmerman from BTIG maintained a Buy rating on GE Healthcare Technologies Inc, with a price target of $87.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ryan Zimmerman has given his Buy rating due to a combination of factors influencing GE Healthcare Technologies Inc. One significant reason is the robust growth potential within the Pharmaceutical Diagnostics segment, which contributes significantly to the company’s revenue. The segment has shown impressive year-over-year growth, and future expectations remain optimistic with high single-digit growth anticipated.
Additionally, strategic partnerships, such as those with Cardiovascular Associates of America and CardioNavix, are expected to drive the adoption of Flyrcado, potentially unlocking a substantial revenue opportunity. Despite some competitive challenges, such as the introduction of a generic version of Omnipaque, GEHC’s valuation remains attractive. The company’s price target is set at $87, based on a multiple that reflects both improved execution and broader macroeconomic risks, positioning it favorably compared to its large-cap peers.